

Bevacizumab

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ADJUSTMENTS

Quality of life

Not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects

Other adjustments

Bevacizumab

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: First-line, unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology

Experimental Arm: Bevacizumab + Paclitaxel + carboplatin

Control Arm: Paclitaxel + carboplatin

